1. Home
  2. MITT vs ACIU Comparison

MITT vs ACIU Comparison

Compare MITT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AG Mortgage Investment Trust Inc.

MITT

AG Mortgage Investment Trust Inc.

HOLD

Current Price

$5.46

Market Cap

245.5M

Sector

Real Estate

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.50

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITT
ACIU
Founded
2011
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.5M
247.6M
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
MITT
ACIU
Price
$5.46
$2.50
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
★ $8.58
$8.57
AVG Volume (30 Days)
★ 413.7K
201.4K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
★ 18.01%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.01
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$422.39
Revenue Next Year
$11.69
$377.85
P/E Ratio
$533.50
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.20
$2.10
52 Week High
$9.27
$4.00

Technical Indicators

Market Signals
Indicator
MITT
ACIU
Relative Strength Index (RSI) 38.52 45.80
Support Level N/A $2.40
Resistance Level $8.00 $2.68
Average True Range (ATR) 0.18 0.09
MACD 0.01 -0.00
Stochastic Oscillator 33.56 34.18

Price Performance

Historical Comparison
MITT
ACIU

About MITT AG Mortgage Investment Trust Inc.

TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: